Press releases

Press releases.

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

November 22nd 2023
press releases

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

November 9th 2023
press releases

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

November 6th 2023
press releases
more

Investor updates

Investor updates.

Investor Update - August 2023

August 18th 2023
investor updates

Investor Update - November 2022

November 17th 2022
investor updates

Investor Update ASCO 2022 Special Edition June 2022

June 17th 2022
investor updates
more

Analyst reports

Analyst reports.

Baird - F1Q24: Encouraged by Efti Data in 1L NSCLC and Beyond; Reit Outperform, $7 tgt (Analyst: Joel L. Beatty, MD, CFA)

For a copy of this research report please contact your Baird advisor

November 1st 2023
analyst reports

Ladenburg Thalmann - Impressive in Lung Cancer, Next is Head and Neck, This Time Placebo-Controlled; Rated Buy, $8.30 PT

For a copy of this research report please contact your Ladenburg Thalmann advisor

November 1st 2023
analyst reports

goetzpartners securities - Changing the game in lung cancer survival; Reit Buy, A$2.88 tgt (Analyst: Dr Chris Redhead)

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

October 30th 2023
analyst reports
more


E-MAIL UPDATES

registration.

Please fill out the registration form below to receive updates and announcements by e-mail.